Progressive Relapsing Multiple Sclerosis (PRMS) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Progressive Relapsing Multiple Sclerosis (PRMS) – Pipeline Review, H2 2016’, provides an overview of the Progressive Relapsing Multiple Sclerosis (PRMS) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Progressive Relapsing Multiple Sclerosis (PRMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Progressive Relapsing Multiple Sclerosis (PRMS) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Progressive Relapsing Multiple Sclerosis (PRMS)

The report reviews pipeline therapeutics for Progressive Relapsing Multiple Sclerosis (PRMS) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Progressive Relapsing Multiple Sclerosis (PRMS) therapeutics and enlists all their major and minor projects

The report assesses Progressive Relapsing Multiple Sclerosis (PRMS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Progressive Relapsing Multiple Sclerosis (PRMS)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Progressive Relapsing Multiple Sclerosis (PRMS)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Progressive Relapsing Multiple Sclerosis (PRMS) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Cognosci Inc

Genzyme Corp

MedImmune LLC

VivaCell Biotechnology Espana SL

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Progressive Relapsing Multiple Sclerosis (PRMS) Overview 6

Therapeutics Development 7

Pipeline Products for Progressive Relapsing Multiple Sclerosis (PRMS) - Overview 7

Progressive Relapsing Multiple Sclerosis (PRMS) - Therapeutics under Development by Companies 8

Progressive Relapsing Multiple Sclerosis (PRMS) - Pipeline Products Glance 9

Clinical Stage Products 9

Early Stage Products 10

Progressive Relapsing Multiple Sclerosis (PRMS) - Products under Development by Companies 11

Progressive Relapsing Multiple Sclerosis (PRMS) - Companies Involved in Therapeutics Development 12

Cognosci Inc 12

Genzyme Corp 13

MedImmune LLC 14

VivaCell Biotechnology Espana SL 15

Progressive Relapsing Multiple Sclerosis (PRMS) - Therapeutics Assessment 16

Assessment by Monotherapy Products 16

Assessment by Target 17

Assessment by Mechanism of Action 19

Assessment by Route of Administration 21

Assessment by Molecule Type 23

Drug Profiles 25

COG-112 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

COG-133 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

GZ-402668 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

inebilizumab - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

VCE-0032 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Progressive Relapsing Multiple Sclerosis (PRMS) - Dormant Projects 32

Progressive Relapsing Multiple Sclerosis (PRMS) - Discontinued Products 33

Appendix 34

Methodology 34

Coverage 34

Secondary Research 34

Primary Research 34

Expert Panel Validation 34

Contact Us 34

Disclaimer 35

List of Tables

List of Tables

Number of Products under Development for Progressive Relapsing Multiple Sclerosis (PRMS), H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Comparative Analysis by Early Stage Development, H2 2016 10

Products under Development by Companies, H2 2016 11

Progressive Relapsing Multiple Sclerosis (PRMS) – Pipeline by Cognosci Inc, H2 2016 12

Progressive Relapsing Multiple Sclerosis (PRMS) – Pipeline by Genzyme Corp, H2 2016 13

Progressive Relapsing Multiple Sclerosis (PRMS) – Pipeline by MedImmune LLC, H2 2016 14

Progressive Relapsing Multiple Sclerosis (PRMS) – Pipeline by VivaCell Biotechnology Espana SL, H2 2016 15

Assessment by Monotherapy Products, H2 2016 16

Number of Products by Stage and Target, H2 2016 18

Number of Products by Stage and Mechanism of Action, H2 2016 20

Number of Products by Stage and Route of Administration, H2 2016 22

Number of Products by Stage and Molecule Type, H2 2016 24

Progressive Relapsing Multiple Sclerosis (PRMS) – Dormant Projects, H2 2016 32

Progressive Relapsing Multiple Sclerosis (PRMS) – Discontinued Products, H2 2016 33

List of Figures

List of Figures

Number of Products under Development for Progressive Relapsing Multiple Sclerosis (PRMS), H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Assessment by Monotherapy Products, H2 2016 16

Number of Products by Targets, H2 2016 17

Number of Products by Stage and Targets, H2 2016 17

Number of Products by Mechanism of Actions, H2 2016 19

Number of Products by Stage and Mechanism of Actions, H2 2016 19

Number of Products by Routes of Administration, H2 2016 21

Number of Products by Stage and Routes of Administration, H2 2016 21

Number of Products by Molecule Types, H2 2016 23

Number of Products by Stage and Molecule Types, H2 2016 23

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports